NeoSENTIA NIPD Genetics Liquid Biopsy Cancer Logo (WIPO, 08.06.2020)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke NeoSENTIA NIPD Genetics Liquid Biopsy Cancer wurde als Bildmarke am 08.06.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Briefe, die eine besondere Form des Schreibens darstellen #Farben #Buchstabenreihen in verschiedenen Dimensionen #Zwei vorherrschende Farben
| Markenform | Bildmarke |
| Aktenzeichen | 1545721 |
| Registernummer | 018191806 |
| Länder | 
|
| Basismarke |
Nr. 018191806,
29. Mai 2020
|
| Anmeldedatum | 08. Juni 2020 |
| Ablaufdatum | 08. Juni 2030 |
Markeninhaber
31, Neas Engomis, Engomi
2409 Nicosia
CY
2409 Nicosia
CY
Markenvertreter
2-4, Arch. Makaros III Avenue,
Capital Center, 7th floor
CY
Waren und Dienstleistungen
01
Kits composed of reagents for genetic testing for medical
and scientific research purposes; kits composed of reagents
for genetic testing for medical and scientific research
purposes in the field of oncology; kits composed of reagents
for cancer diagnosis and prognosis for medical and
scientific research purposes; kits composed of reagents for
testing for chromosomal or mutational abnormalities in
cancer patients for medical and scientific research
purposes
42
Medical laboratory services for cancer testing; design and
development of medical diagnostic tests and products;
medical and scientific research in the field of genetic
testing particularly in the field of oncology; providing
medical and scientific research information in the field of
genetic testing; genetic testing for scientific research and
analysis purposes in the field of oncology cancer; genetic
engineering services
44
Medical testing services for diagnosis of cancer; medical
genetic screening testing; medical diagnostic testing in the
field of oncology; medical testing of blood for diagnosis of
genetic abnormalities such as mutations during cancer
disease; medical testing for diagnosis of genetic disorders,
diseases and syndromes; genetic testing and genetic
counseling in the field of cancer treatment; medical and
health services relating to DNA, genetics and genetic
testing
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 27. Januar 2022 | 2022/5 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 05. August 2021 | 2021/31 Gaz | JP | Ablehnung |
| 29. Juli 2021 | 2021/30 Gaz | UA | Ablehnung |
| 30. Juni 2021 | 2021/30 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 05. März 2021 | 2021/10 Gaz | IL | Ablehnung |
| 01. März 2021 | 2021/9 Gaz | IN | Ablehnung |
| 08. Februar 2021 | 2021/6 Gaz | RU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 05. Februar 2021 | 2021/6 Gaz | SG | Ablehnung |
| 04. Februar 2021 | 2021/6 Gaz | RS | Ablehnung |
| 23. Dezember 2020 | 2020/53 Gaz | TR | Ablehnung |
| 01. Dezember 2020 | 2020/50 Gaz | RU | Ablehnung |
| 01. Oktober 2020 | 2020/40 Gaz | US | Ablehnung |
| 08. Juni 2020 | 2020/31 Gaz | EM | Eintragung |
ID: 141545721